ABVC BioPharma Reports No Revenue and $3.3 Million Net Loss for First Half of 2025

ABVC BioPharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded no revenue for the quarter, a decrease from $117,142 in the same period last year. For the six months ending June 30, 2025, ABVC also reported no revenue, compared to $118,347 for the same period in 2024. The company incurred a net loss of $3.3 million for the first half of 2025, a slight improvement from a loss of $4 million in the prior year. The loss per share for the quarter was $(0.13), compared to $(0.08) in the previous year.

ABVC's total assets increased significantly to $16.2 million as of June 30, 2025, up from $7.5 million at the end of 2024. This growth was primarily driven by a substantial increase in property and equipment, which rose to $8.2 million from $511,088, largely due to the acquisition of land in Taiwan valued at $7.7 million. The company's total equity also saw a notable rise, reaching $9.5 million, compared to $723,959 at the end of 2024, reflecting a successful capital raise through the issuance of common stock and warrants.

Operationally, ABVC has made strides in its strategic initiatives, including the acquisition of AiBtl BioPharma, which has expanded its product pipeline in the central nervous system (CNS) drug market. The company is actively pursuing collaborative agreements to develop and commercialize various drug products, including those targeting major depressive disorder and attention deficit hyperactivity disorder. As of June 30, 2025, ABVC's employee headcount has increased, reflecting its ongoing expansion efforts.

The company has also faced challenges, including a working capital deficit of $2.8 million and net cash outflows of $1.4 million from operating activities for the first half of 2025. Management has indicated that to sustain operations, it may need to secure additional financing through private or public offerings, or support from related parties. The company remains focused on improving its operational efficiency and generating positive cash flows to mitigate concerns regarding its ability to continue as a going concern.

Looking ahead, ABVC BioPharma is optimistic about its future prospects, particularly with the ongoing development of its drug pipeline and potential revenue from collaborative agreements. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, including market conditions and regulatory challenges, which could impact its financial performance and operational plans.